TScan Therapeutics
TCRX
TCRX
54 hedge funds and large institutions have $187M invested in TScan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 0 closing their positions.
Holders
54
Holders Change
+22
Holders Change %
+68.75%
% of All Funds
0.79%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
22
Increased
13
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PBM
1
Propel Bio Management
Los Angeles,
California
|
$12.2M |
| 2 |
2
Morgan Stanley
New York
|
$2.74M |
| 3 |
3
Aberdeen Group
Edinburgh,
United Kingdom
|
$1.17M |
| 4 |
4
Marshall Wace
London,
United Kingdom
|
$645K |
| 5 |
5
Millennium Management
New York
|
$578K |
Top Sellers
| 1 |
1
Adage Capital Partners
Boston,
Massachusetts
|
$22.7M |
| 2 |
LBA
2
Letko, Brosseau & Associates
Montreal,
Quebec, Canada
|
$121K |
| 3 |
3
BlackRock
New York
|
$9.75M |
| 4 |
4
Northern Trust
Chicago,
Illinois
|
$417K |
